Thanks Stellowe - I'll do that. That explains it somewhat. Seems unlikely they would orchestrate a trial then. Seems more likely it would receive label extension through Ryoncil (or Rem-l), provided results remain positive. Do you know if a 'drug/treatment' can receive a label extension if it has only been approved under AA or does AA only apply to the indication it was approved for? TIA
Ann: COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C, page-55
-
- There are more pages in this discussion • 105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |